CAC2 Childhood Cancer Community News Digest (March 10-16)

March 17, 2025 Community News, Guest Blogs, News Digest

Assorted News from the Last Week:

CAC2 Member Blog from Stan Robbins–Awareness & Entertainment Opportunity: Audrey’s Children

Childhood cancer survivors have a more than two-fold increased risk of developing melanoma during their lifetime, compared to the general population, as well as a two-fold increased risk of death associated with a melanoma diagnosis.

Suicidal ideation significantly higher among childhood cancer survivors.

Newborns with heart defects may face a higher risk of developing childhood cancer.

New therapeutic approach shows promise for pediatric high-grade gliomas.

New NCI Pediatric Preclinical In Vivo Testing Consortium (PIVOT) study data are in the CCDI Data Ecosystem. The data are from molecular testing results from pediatric acute lymphoblastic leukemia (ALL) and neuroblastoma patient-derived xenograft (PDX) models. Included are data from next-generation sequencing and whole-genome chromosome analysis.

Blinatumomab boosts chemotherapy as initial treatment for some kids with ALL.

Upcoming Webinars, Online Opportunities, and Meetings:

Wipe Out Kids’ Cancer (WOKC) is teaming up with 88 Jersey Mike’s Subs locations across DFW in March to raise funds in the fight against pediatric cancer. As part of Jersey Mike’s 15th Annual Month of Giving, the campaign will culminate on Wednesday, March 26, with 100% of all sales donated to WOKC in support of DFW kids (and their families) battling cancer.  Click here for more information.

 

The Coalition Against Childhood Cancer will hold its 2025 Annual Summit, hosted by Children’s National Hospital in Washington DC and presented by Day One Biopharmaceuticals. This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing efforts of our members who are working for a future without childhood cancers.  June 15-17.  Register here: CAC2 Annual Summit Registration

Cheerful Hearts hosts online game time for children ages 6 through 14 years old every Sunday at 4:00 pm-4:30 EST. Click here for more information and to register.

Recent Recordings:

Global Platform for Access to Childhood Cancer Medicines.

January CCDI webinar, “Unlock the Power of Unstructured Data with EMERSE,” is now available

Take Action:

CAC2 Member Kylee McGrane (A Moment of Magic) is currently up for a $25,000 prize to support the mental health and wellbeing of children with cancer and other serious illnesses. Click here for more information and to vote for Kylee.

CAC2 Innovation Council Recommendation: ARYA-2 Clinical Trial for Pediatric Liver Cancer

Overview of the Opportunity: This request concerns a Phase 1/2 clinical trial, evaluating ET140203 T Cells in pediatric patients with relapsed/refractory Hepatoblastoma, Hepatocellular Neoplasm-Not Otherwise Specified, or Hepatocellular Carcinoma.

The Requester: Nicole Nunez, Associate Director of Patient Engagement and Regulatory Affairs (PhD), Eureka Therapeutics, Inc.

The Type of Request: Information sharing about a clinical trial opportunity for children with liver cancer.  Sharing information about a trial does not imply that CAC2 is recommending or endorsing. Each patient should check with their medical professionals.

The Ask:  Inform CAC2 Members about the ARYA-2 clinical trial (NCT04634357) which is a multi-center, Phase 1/2 clinical trial currently in the dose escalation phase, evaluating ET140203 T Cells in pediatric patients with relapsed/refractory Hepatoblastoma, Hepatocellular Neoplasm-Not Otherwise Specified, or Hepatocellular Carcinoma.

Please share the clinical trial flyer and help connect the trial team with any entities that can help bring awareness about this trial. Since pediatric liver cancer is an ultra rare disease (less than 200 kids diagnosed every year in the US), the trial team is doing everything it can to let doctors, patients and patient community groups know that this trial is open and actively recruiting.

Supporting Documentation: The trial is currently open at Dana-Farber Boston Children’s Cancer Institute, UCSF Benioff Children’s Hospitals, and Children’s Hospital Los Angeles. Autologous ET140203 T-cell therapy is designed to specifically target and destroy AFP/HLA-A2-positive liver cancer, while minimizing potential side effects traditionally associated with cancer treatment.

Eureka Therapeutics provides financial support for the patient and one caregiver to cover travel, food and accommodations during their participation in the trial.

Informational Flyer: https://drive.google.com/file/d/1fYAQL-yBVbzV4lv4xrKYEUQUmin7GR0R/view?usp=share_link

Patient friendly website at: www.eurekaconnectme.com

Corporate website is: www.eurekatherapeutics.com

For more information on the clinical trial, including details regarding eligibility criteria, please visit the clinicaltrials.gov website page: https://clinicaltrials.gov/study/NCT04634357

 

SUBSCRIBE

Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

Name(Required)
Email(Required)
This field is for validation purposes and should be left unchanged.

Archives

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.